Collaboration combines AI technology and operational expertise to help life sciences organizations scale intelligent automation across global safety operations 

Boston, Massachusetts – June 2, 2026 – ArisGlobal, an AI-first technology company at the forefront of life sciences and creator of LifeSphere®,  today announced an expanded strategic partnership with Sitero, a global provider of technology-enabled safety and clinical research services, to further advance AI-driven innovation across pharmacovigilance operations. 

The expanded collaboration builds on the companies’ existing relationship and shared focus on helping life sciences organizations move beyond AI experimentation toward scalable, real-world operational impact in safety operations. 

As part of the partnership, ArisGlobal and Sitero are expanding intelligent automation across Literature Search & Monitoring and End-to-End Case Management by combining ArisGlobal’s LifeSphere Safety platform and NavaX™ AI engine with Sitero’s deep operational expertise supporting global pharmaceutical organizations. Together, the companies bring hands-on experience managing complex safety environments and implementing AI-driven workflows designed to improve efficiency, consistency, and scalability across safety operations. 

“Life sciences organizations are increasingly focused on how to operationalize trusted AI across real-world safety environments,” said Aman Wasan, CEO of ArisGlobal. “Our continued collaboration with Sitero reflects a shared commitment to helping customers accelerate AI adoption through flexible technology, operational expertise, and practical innovation.” 

“As organizations look to scale AI within pharmacovigilance, there is growing demand for solutions that reduce manual effort, improve consistency, and support more efficient global operations,” said Sankesh Abbhi, CEO of Sitero. “Our partnership with ArisGlobal combines Sitero’s hands-on PV operations experience with ArisGlobal’s advanced AI capabilities to help customers drive measurable transformation across safety workflows.” 

Together, the companies continue to support the evolution of AI-enabled pharmacovigilance through connected technology, operational collaboration, and practical innovation that can scale with global safety needs.